News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
109–144
Matches
274
Sources here
22
Companies here
10
Search results Stored financial headlines

Active search

274 matching headlines

Ticker or company: POLYMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid has announced an exclusive commercial partnership with Azurity Pharmaceuticals for the U.S. and Canadian commercialization of D-PLEX₁₀₀, a drug designed to prevent surgical site infections. PolyPid stands to receive over $320 million in potential payments, including an initial $30 million upfront and near-term …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid - Eligible for up to $300 Mln in Addi

This article announces that PolyPid is eligible for up to $300 million in additional funding. The exact nature of this funding (e.g., grants, investments, milestone payments) is not detailed in the provided content. The brief title suggests a significant financial boost for the company.

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid, Azurity sign surgical site infection drug deal

Israeli biotech PolyPid has signed a deal with Azurity Pharmaceuticals to commercialize its D-PLEX100 drug, aimed at preventing surgical site infections, in the U.S. and Canada. The agreement could bring PolyPid over $320 million, including an initial $15 million and potential milestone payments. PolyPid …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3

PolyPid has entered into an exclusive commercial partnership with Azurity Pharmaceuticals for its D-PLEX100 product in the U.S. and Canada, aimed at preventing surgical site infections. The deal, valued at over $320 million, includes upfront payments, milestones, and royalties, building on positive Phase 3 …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada

PolyPid Ltd. announced an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100, aimed at preventing surgical site infections in the U.S. and Canada. The deal includes an upfront payment of $15 million, an additional $15 million upon FDA acceptance of the New Drug Application, …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn). The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide's fully diluted share capital, excluding treasury shares. Completion of the deal is anticipated …

PPGN main company
Sharemaestro market context Trend signal active 52 weeks +56.4% PPGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion. Strong transaction support, with a unanimous recommendation from …

PPGN main company
Sharemaestro market context Trend signal active 52 weeks +56.4% PPGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Polyrizon Shareholders Approve New Executive Compensation Policy on July 13, 2026

Polyrizon Ltd. shareholders approved a new executive compensation policy on July 13, 2026, during their annual general meeting in Raanana. The policy, effective for three years, includes base salary, benefits, cash bonuses, and equity awards, with variable pay capped at 95% of total compensation …

PLRZ main company
Sharemaestro market context Price below Trend Line 52 weeks +69.4% PLRZ stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid (PYPD) awards CFO 49,000 stock options at $4.46

PolyPid Ltd. (PYPD) reported that its Chief Financial Officer, Jonathan Missulawin, was granted 49,000 stock options on May 11, 2026. These options have an exercise price of $4.46 per share, an exercise date of August 11, 2026, and expire on May 11, 2036. The …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid (NASDAQ: PYPD) grants 46,000 stock options to U.S. COO

PolyPid Ltd. (NASDAQ: PYPD) has granted its U.S. Chief Operating Officer, Ori Warshavsky, an option to purchase 46,000 ordinary shares with an exercise price of $4.46 per share. These options will vest quarterly from May 11, 2026, to May 11, 2030, and are set …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid (PYPD) grants director Dror-Darwish Nir 9,132 stock options at $4.46

PolyPid Ltd. (PYPD) director Dror-Darwish Nir was granted 9,132 stock options at an exercise price of $4.46 per share. These options will vest quarterly starting July 15, 2026, until April 15, 2030, and are set to expire on July 15, 2036. This transaction is …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Frontier tech research, news & data

The article reports on an insider transaction for PolyPid Ltd. filed on July 17, 2026. It also mentions a research report titled "The Power Delivery Gap" which analyzes the US grid's capacity to deliver renewable and firm gas power based on interconnection queue data.

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

PolyPid Ltd. (PYPD) boosts option pool by 1.5M shares and clears CEO grant

PolyPid Ltd. (PYPD) held its Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where all four proposals were approved, including the re-election of auditors and directors, amendments to non-executive directors' option grants, and an option grant for CEO Dikla Czaczkes Akselbrad. …

PYPD main company
Sharemaestro market context Trend signal active 52 weeks +35.4% · Next-week setup positive 58.0% PYPD stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context